학술논문
Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma
Document Type
Editorial
Author
Source
In: Journal of Thoracic Oncology . (Journal of Thoracic Oncology, January 2022, 17(1):30-33)
Subject
Language
English
ISSN
15561380
15560864
15560864